|Bid||62.95 x 3100|
|Ask||63.00 x 1100|
|Day's range||62.15 - 62.99|
|52-week range||57.17 - 74.12|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||19.25|
|Earnings date||26 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||2.92 (4.74%)|
|Ex-dividend date||14 Sept 2022|
|1y target est||69.79|
If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.
FOSTER CITY, Calif., August 09, 2022--Gilead Sciences, Inc. (Nasdaq: GILD), GLAAD, the Human Rights Campaign (HRC), the National Black Justice Coalition (NBJC), the National Center for Lesbian Rights (NCLR) and NMAC today announced immediate action in response to the emerging monkeypox virus (MPV) outbreak, which is disproportionately impacting the LGBTQ+ community, particularly men who have sex with men (MSM), as well as those who are living with HIV. Gilead will provide up to $5 million in glo
Gilead Sciences (NASDAQ: GILD) has kept its revenue and earnings growing in the past two years -- if ever so slightly -- largely thanks to Veklury, its COVID-19 therapy. Gilead Sciences' revenue rose by only about 1% year over year to $6.3 billion during the period. Excluding sales of Veklury, which dropped by 46% year over year to $445 million, Gilead Sciences' revenue for the quarter grew by a more impressive and respectable (by industry standards) 7%.